In short: buy the parts of the stack that are not your advantage (the model, the interface, the generic tooling) and build, or own, the parts that are (your commercial data, your territory definitions, the workflow your people actually run). The build-or-buy question only feels hard because it is usually asked about the whole thing at once. Asked layer by layer, it answers itself.
Every commercial leader in Indian pharma is being told two things at the same time. Build your own AI, because your data is your moat and you cannot outsource your edge. And buy this platform, because building is slow and you are not a software company. Both pieces of advice are correct about something and wrong about the thing they are usually applied to. This piece is about how to tell which is which for a specific workload, without running the eighteen-month pilot that settles it the expensive way.
The short answer
There is no single build-or-buy decision. There is a build-or-buy decision for each layer of the workload, and the layers have different answers. The foundation model is a buy for almost everyone. The commercial data foundation underneath it is a build, or at least an own. The workflow in between, the part that turns a model output into a decision a Brand Manager will act on, is the part worth arguing about, and it is usually a hybrid.
Teams that treat "AI" as one monolithic build-or-buy choice make the wrong call in both directions: they build undifferentiated plumbing they could have bought, and they buy a black box sitting on top of the one asset (their data) that was supposed to be the point.
The two questions that actually decide it
For any given workload, two questions settle the call.
Is this layer your competitive advantage, or is it table stakes? A frontier language model is table stakes; you will never out-train GPT, Claude, or Gemini, and you should not try. Your reconciled view of how your brands move across IQVIA and SMSRC at the territory level is competitive advantage; nobody else has it and it is the substrate every useful workload runs on. Buy table stakes. Own advantage.
Do you have the people to operate it after launch, not just to ship it? This is the question vendors and internal champions both skip. A bought platform that nobody on the commercial side owns dies in the second review cycle. A built system with no engineer to maintain the territory master decays the first time the org reshuffles. Build-or-buy is not really about who writes the code; it is about who is accountable for the workload the day after it goes live. If the honest answer is "nobody yet," that is the thing to fix before the technology choice, and it is the reason the org chart sits behind the roadmap.
When buying is the right call
Buy when the workload is genuinely common, the data it needs is not uniquely yours, and the value is in speed-to-deployed rather than in differentiation. Buy the foundation model, always. Buy the generic interface layer, the retrieval plumbing, the eval tooling, the observability, the things a hundred other companies need in identical form. Buy when your commercial team needs the capability this quarter and the workflow is standard enough that a vendor who has shipped it ten times will get you there faster than your team building it once.
The trap in buying is the black box on top of your own data. A platform that ingests your commercial feeds and returns a recommendation you cannot trace back to a primary, secondary, IQVIA, or SMSRC source is not a time-saver; it is a credibility risk that surfaces the first time the number disagrees with the Brand Manager's gut. Buy the engine. Do not buy away your ability to explain the answer.
When building is the right call
Build when the workload sits on data only you have, in a shape only you understand, serving a decision only your people make. The clearest example is the layer almost nobody can buy off the shelf: getting your sales, prescription, and market data onto one consistent map of your territories. No vendor arrives with your field structure, your stockist quirks, your SKU master, or your org-change history. That layer is build-or-own by necessity, and it is the layer that decides whether everything above it is trustworthy. It is also where most teams should start.
Build, too, when the workflow is your actual edge: a call-plan re-ranking that encodes how your sales excellence team thinks, an attribution view tuned to how your Brand Managers are measured. These are not features a platform ships; they are your operating model expressed in software. The cost of building them is real. The cost of renting them is that your edge now lives on someone else's roadmap.
The hybrid most teams land on
In practice the answer is almost never pure. The shape that works for most Indian pharma commercial teams is: buy the model and the generic tooling, own the data foundation, and build the thin workflow layer that is yours. A bought frontier model does the reading and reasoning. Your owned, reconciled data foundation feeds it numbers your people trust. A small built layer, often just prompts, evals, and a review loop rather than a large system, turns model output into a decision your Brand Manager or Territory Manager will act on, in their vocabulary, traceable to source.
This is also the cheapest path that does not mortgage your advantage. The expensive mistakes are the two extremes: building the foundation model (impossible) or buying the workflow that was supposed to be your edge (self-defeating). The middle is not a compromise; it is the correct architecture.
Why this belongs in the consortium
Build-or-buy is the question where a single honest conversation with a peer who has already shipped saves a year. The vendor cannot give you that conversation; their answer is structurally "buy." Your own team's answer drifts toward "build," because building is what they want to do. The person who can actually calibrate you is the commercial leader two companies over who made the call last year and watched it play out, and the engineer who built the thing and knows which 80% was harder than the pitch admitted.
That is the room AI for Pharma is convened to host: commercial leaders and the people building for them, in the same room, on a recurring schedule, working through exactly this kind of decision before the eighteen-month pilot settles it the expensive way. If build-or-buy is the question on your desk, apply.